181 related articles for article (PubMed ID: 7554993)
1. Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis.
Miyata T; Wada Y; Maeda K
Contrib Nephrol; 1995; 112():52-64. PubMed ID: 7554993
[No Abstract] [Full Text] [Related]
2. New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction.
Miyata T; Maeda K
Nephrol Dial Transplant; 1996; 11 Suppl 2():140-3. PubMed ID: 8804015
[No Abstract] [Full Text] [Related]
3. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis.
Miyata T; Sprague SM
Nephrol Dial Transplant; 1996; 11 Suppl 3():86-90. PubMed ID: 8840320
[No Abstract] [Full Text] [Related]
4. Pathogenesis of dialysis-related amyloidosis.
Miyata T; Maeda K
Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):493-7. PubMed ID: 8591057
[TBL] [Abstract][Full Text] [Related]
5. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis.
Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF
Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467
[TBL] [Abstract][Full Text] [Related]
6. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y
Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of advanced glycation end-products in renal failure.
Miyata T; Iida Y; Horie K; Cai Z; Sugiyama S; Maeda K
Nephrol Dial Transplant; 1996; 11 Suppl 5():27-30. PubMed ID: 9044303
[TBL] [Abstract][Full Text] [Related]
8. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
[TBL] [Abstract][Full Text] [Related]
9. Molecular heterogeneity of amyloid beta2-microglobulin and modification with advanced glycation end products.
Mironova R; Niwa T
J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(1):109-15. PubMed ID: 11482729
[TBL] [Abstract][Full Text] [Related]
10. Beta-2 microglobulin in ESRD: an in-depth review.
Winchester JF; Salsberg JA; Levin NW
Adv Ren Replace Ther; 2003 Oct; 10(4):279-309. PubMed ID: 14681859
[TBL] [Abstract][Full Text] [Related]
11. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
Miyata T
Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
[TBL] [Abstract][Full Text] [Related]
12. Beta2-Microglobulin dialysis amyloid and its formation: role of 3-deoxyglucosone and advanced glycation end products.
Niwa T
Nephron; 1997; 76(4):373-91. PubMed ID: 9274834
[No Abstract] [Full Text] [Related]
13. Implication of the glycoxidation and lipoxidation reactions in the pathogenesis of dialysis-related amyloidosis (Review).
Sugiyama S; Miyata T; Inagi R; Kurokawa K
Int J Mol Med; 1998 Nov; 2(5):561-5. PubMed ID: 9858652
[TBL] [Abstract][Full Text] [Related]
14. Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis.
Iida Y; Miyata T; Inagi R; Sugiyama S; Maeda K
Biochem Biophys Res Commun; 1994 Jun; 201(3):1235-41. PubMed ID: 8024566
[TBL] [Abstract][Full Text] [Related]
15. Amyloid, advanced glycation end products, and dialysis related arthropathy.
McDonald SP; Coates PT; Disney AP
Ann Rheum Dis; 1998 Apr; 57(4):193-5. PubMed ID: 9709172
[No Abstract] [Full Text] [Related]
16. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products.
Miyata T; Iida Y; Ueda Y; Shinzato T; Seo H; Monnier VM; Maeda K; Wada Y
Kidney Int; 1996 Feb; 49(2):538-50. PubMed ID: 8821842
[TBL] [Abstract][Full Text] [Related]
17. 'Carbonyl stress' and dialysis-related amyloidosis.
Miyata T; Ueda Y; Saito A; Kurokawa K
Nephrol Dial Transplant; 2000; 15 Suppl 1():25-8. PubMed ID: 10737163
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis.
Miyata T; Inagi R; Kurokawa K
Miner Electrolyte Metab; 1999; 25(1-2):114-7. PubMed ID: 10207272
[TBL] [Abstract][Full Text] [Related]
19. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.
Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H
J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390
[TBL] [Abstract][Full Text] [Related]
20. [Amyloidosis in patients undergoing long-term hemodialysis: elucidation of etiological mechanism and therapeutic stratigy].
Shimojyo F
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():56-60. PubMed ID: 15796057
[No Abstract] [Full Text] [Related]
[Next] [New Search]
